It’s the Truvada conundrum: A drug hailed as a lifesaver for many people infected by HIV is at the heart of a rancorous debate among gay men, AIDS activists and health professionals over its potential for protecting uninfected men who engage in gay sex without using condoms.
Published: April 7, 2014
Many doctors and activists see immense promise for such preventive use of Truvada, and are campaigning hard to raise awareness of it as a crucial step toward reducing new HIV infections, which now total about 50,000 a year in the U.S. Recent efforts range from think-tank forums and informational websites to a festive event at a New York City bar featuring popular drag queens.
Yet others – despite mounting evidence of Truvada’s effectiveness – say such efforts are reckless, tempting some condom users to abandon that layer of protection and exposing them to an array of other sexually transmitted infections aside from HIV.
"If something comes along that’s better than condoms, I’m all for it, but Truvada is not that," said Michael Weinstein, president of the AIDS Healthcare Foundation. "Let’s be honest: It’s a party drug."
Even as gay-rights organizations celebrate collective progress in the fight to legalize same-sex marriage, the less-publicized Truvada debate has fueled bitter divisions within the gay community. Some who use the drug say they’ve felt shamed by some who don’t, and there’s now a lively backlash by users and their allies, including promotion of a "Truvada Whore" T-shirt.
"The discussion can torch emotions like a flame-thrower on a fuel depot," wrote Steve Ramos of the Dallas Voice as the gay-oriented publication reported on the debate in March.
Truvada, produced by California-based Gilead Sciences, has been around for a decade, serving as one of the key drugs used in combination with others as the basic treatment for people who have the AIDS-causing virus HIV. However, the drug took on a more contentious aspect in 2012 when the Food and Drug Administration approved it for pre-exposure prophylaxis, or PrEP – in other words, for use to prevent people from getting sexually transmitted HIV in the first place.
Since then, critics have warned that many gay men won’t heed Truvada’s once-a-day regimen and complained of its high cost – roughly $13,000 a year. Truvada’s proponents say most insurance plans – including Medicaid programs – now cover prescriptions for it, and they cite studies showing that the blue pill, if taken diligently, can reduce the risk of getting HIV by more than 90 percent.
Full text of article available at link below –